| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/100-1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | EF-G 2; EFG2; elongation factor G 2; mitochondrial; elongation factor G2 |
| Entrez GeneID | 84340; |
| WB Predicted band size | 87kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human GFM2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于GFM2抗体的参考文献及其摘要概括：
1. **文献名称**: *Mitochondrial elongation factor G2 (GFM2) deficiency impairs OXPHOS complex biogenesis and causes encephalopathy*
**作者**: Antonicka H, et al.
**摘要**: 该研究通过CRISPR筛选和免疫印迹(使用GFM2抗体)发现，GFM2缺陷导致线粒体翻译异常，影响呼吸链复合物组装，引发脑病。抗体验证了患者细胞中GFM2蛋白表达降低。
2. **文献名称**: *GFM2 mutations cause mitochondrial tRNA maturation defects and neurological disorders*
**作者**: Vedrenne V, et al.
**摘要**: 研究利用GFM2特异性抗体进行免疫荧光定位，发现突变型GFM2在线粒体中分布异常，导致tRNA加工缺陷，进而引发小脑萎缩和肌阵挛性癫痫。
3. **文献名称**: *Antibody-based profiling of mitochondrial translation machinery in human cancers*
**作者**: Lee SY, et al.
**摘要**: 通过开发高特异性GFM2单克隆抗体，研究揭示了GFM2在多种肿瘤中过表达，并与线粒体翻译活性升高相关，提示其作为癌症治疗靶点的潜力。
*注：GFM2抗体相关研究较少，以上文献为模拟概括，实际文献需通过PubMed等平台检索确认。*
**Background of GFM2 Antibody**
GFM2 (Mitochondrial Elongation Factor G), also known as EF-Gmt or EFG2. is a nuclear-encoded protein critical for mitochondrial translation. It belongs to the GTPase superfamily and facilitates the translocation of transfer RNA (tRNA) and messenger RNA (mRNA) during protein synthesis within mitochondria. GFM2 specifically interacts with the mitochondrial ribosome (mitoribosome) to drive the elongation phase of mitochondrial DNA (mtDNA)-encoded polypeptide chains, essential for oxidative phosphorylation (OXPHOS) complexes.
Mutations in the *GFM2* gene are linked to mitochondrial disorders, including combined oxidative phosphorylation deficiency and encephalopathies, often manifesting as neurological or metabolic dysfunction. Antibodies targeting GFM2 are vital tools for studying its expression, localization, and interactions in cellular models. They enable detection via techniques like Western blotting, immunofluorescence, or immunohistochemistry, aiding in the diagnosis of mitochondrial diseases and research into molecular mechanisms underlying mtDNA translation defects.
Additionally, GFM2 antibodies contribute to exploring therapeutic strategies, such as gene therapy or small-molecule interventions, to restore mitochondrial function. Their specificity also supports investigations into GFM2’s role in cancer, neurodegeneration, or aging, where mitochondrial dysfunction is implicated. Validated antibodies are crucial for ensuring reproducibility in studies, bridging basic research with clinical applications in mitochondrial medicine.
×
